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Cancer-related fatigue (CRF) is a common polysymptomatic syndrome with no standard therapy. The authors present the case of a prostate 
cancer patient in whom, during hormone therapy, disabling CRF and urinary incontinence occurred. CRF was assessed according to the 
brief fatigue inventory (BFI). The patient received duloxetine, 60 mg daily, due to its impact on both CRF and incontinence. After 2 months, 
the BFI score decreased (from 9 to 2) and urinary incontinence resolved. After duloxetine discontinuation, the patient maintained a low BFI 
score. The authors conclude that, as a serotonin-noradrenaline reuptake inhibitor, duloxetine could be active on prostate CRF, especially 
with associated urinary symptoms. Therefore, a pilot placebo-controlled trial with duloxetine to treat prostate CRF may be worthwhile.
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INTRODUCTION
According to National Comprehensive Cancer Network 
guidelines, cancer-related fatigue (CRF) is a distressing, 
persistent, subjective sense of physical, emotional and 
cognitive tiredness due to cancer and/or its treatments, 
which is not proportional to real daily living activity.[1] 
Diagnosis of CRF depends on the administration of multi-
dimensional scales, albeit to date the superiority of one 
scale compared to the others is not yet well deﬁned.[2]
Generally, 60-90% of all cancer patients under speciﬁc 
treatment and 30-75% of cancer survivors present CRF.[3] 
It has been reported that about 74% of prostate cancer 
patients experience fatigue.[4] This association is due, in 
part, to the impact that androgen deprivation, the mainstay 
of pharmacological prostate cancer treatment, has on the 
pathophysiological mechanism of CRF.[5]
Most prostate cancer patients receive hormone therapy 
(HT) during their lifetime since it is used for localized 
disease, as neoadjuvant/adjuvant to radiotherapy or 
surgery, or for biochemical relapse following radical local 
treatment. Furthermore, HT often constitutes the sole 
treatment for localized disease in patients unsuitable for 
curative therapy or for metastatic disease. At early stages, 
17% of patients undergoing HT complain about severe 
fatigue.[6] In patients receiving both radiotherapy and HT, 
the prevalence of chronic fatigue is about 39%.[7]
CRF is a complex, polysymptomatic syndrome caused 
by direct and/or indirect effects of neoplastic lesions, 
supportive care management, comorbidities and related 
medications, and environmental and psycho-emotional 
aspects. Although CRF patho-physiology is still not 
completely understood, each of these above mentioned 
factors can cooperate to lead to an abnormal production 
and use of adenosine triphosphate, an increase in pro-
inﬂammatory cytokines, adhesion molecule and acute 
phase proteins. These metabolic changes are responsible 
for sleep-wake rhythm disorders and alterations of central 
nervous system mediators (corticotropin-releasing hormone 
increase, serotonin release and dopamine decrease).[8]
In one study, only 9% of patients with CRF were treated, 
and the rate of success was quite low.[9] At present, no 
satisfactory standard therapy for CRF is available.[10] 
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Corticosteroids can be useful but are not devoid of 
major side effects. Some evidence supports the use of 
methylphenidate over placebo, but its use is limited by 
side effects, and it should be administrated only under 
expert supervision. One placebo-controlled trial on 
methylphenidate in prostate cancer showed a small beneﬁt. 
However, 37.5% of treated subjects dropped out for severe 
drug-related adverse events. Secondly, the sample size was 
quite small, and statistical analysis was not corrected for 
multiple comparisons.[11]
Also, erythropoietin may be effective but a speciﬁc dose for 
routine practice in CRF cannot be recommended. The aim 
of treatment should be to use the minimum required dose 
for the shortest duration.[12] This is due to the theoretical 
increase in the risk of thromboembolic side effects with 
higher doses and protracted treatment with erythropoietin 
and possible cancer stimulation.[10]
In some trials, antidepressants and psychostimulant drugs 
showed a small little clinical beneﬁt.[13] Here, we report a case 
of CRF treated with duloxetine. Duloxetine is a serotonin-
noradrenergic reuptake inhibitor, commonly used as an 
antidepressant. It has been recently approved for neuropathic 
pain, chronic fatigue syndrome (at the dose range of 30-60 mg 
daily), ﬁbromyalgia and it is also recommended for urinary 
incontinence in Europe (40-80 mg daily).[14-16]
CASE REPORT
A 74-year-old man presented to our clinic complaining of 
more than 6 months of fatigue, which was exacerbated by 
activity and not relieved by rest. The patient had a history 
of advanced prostate cancer 3 years before, he underwent 
a radical prostatectomy (Gleason score 4 + 4, pT3bN0; 
prostate-speciﬁc antigen (PSA) 21.1 ng/mL) followed by 
adjuvant radiotherapy. Following treatment, only mild 
urinary incontinence was noted. Two years later, he had a 
biochemical relapse, with a PSA doubling time < 6 months 
for which he started on daily bicalutamide, 50 mg and 
monthly luteinizing hormone-releasing hormone agonist. 
After starting medical therapy, a progressive and signiﬁcant 
PSA normalization was observed. However, 6 months 
later, he complained for recurrent moments of sadness, 
loss of interest in daily activities, insomnia, concentration 
problems and worsening urinary incontinence (from mild 
to moderate).
On physical examination, he was not pale or jaundiced, 
afebrile with normal heart rate and blood pressure. Heart, 
lung, abdominal and musculoskeletal examinations were 
normal. No hepatomegaly, gynecomastia or neurological 
signs were present. Eastern Cooperative Oncology Group 
performance status was 0-1. Laboratory tests, including 
a complete blood count and electrolytes, showed mild 
anemia (hemoglobin 11.7 g/dL) and elevated transaminase 
levels (alanine transaminase 83 U/L, aspartate transaminase 
51 U/L) while thyroid, hepatic and renal function were 
normal. Serological tests for hepatitis B virus, hepatitis 
C virus, human immunodeﬁciency virus, Epstein-
Barr virus and cytomegalovirus were negative. Chest 
radiography, abdominal ultrasound, electrocardiography and 
echocardiography were all normal.
Diagnosis of CRF was established as a diagnosis of 
exclusion. CRF was assessed according to the Brief 
Fatigue Inventory (BFI),[17] and a score of 9 (BFI range, 
0-10) was found.
Considering both the urinary incontinence and depression 
symptoms, we prescribed duloxetine at a starting daily dose 
of 30 mg and then, as per drug schedule, after 2 weeks, the 
dose was increased to 60 mg. Duloxetine was chosen due to 
its efﬁcacy against urinary incontinence at a similar dose 
(dose range, 40-80 mg daily).
After 2 months of treatment at the dose of 60 mg, the BFI 
score was decreased to 2, urinary incontinence completely 
resolved, and the patient returned to regular activities. 
There were no side effects. Duloxetine was continued at 
the same dose for a further 2 months and then was 
withdrawn because of alcoholism relapse, a disorder that 
the patient and his relatives had omitted in medical history. 
After duloxetine discontinuation, the patient reported a 
moderate CRF worsening over 6 months. However, 4 
months later, he maintained a 5 points-lower BFI score 
than the initial one. At the same time, he was referred 
to our alcohol abuse center with a progressive reduction 
of heavy-drinking days in a 6-month timeline follow-back.
DISCUSSION
CRF is a major problem in prostate cancer management, 
according to several studies, the prevalence of CRF 
regardless of intensity is about 74%.[4] There is no 
“gold standard” treatment currently recommended, and 
the commonly given therapies are poorly successful. 
Only 2 drugs have shown some activity against CRF: 
methylphenidate and erythropoietin, although their regular 
use do have caveats.[10]
Our patient, who was not receiving chemotherapy, 
showed mild anemia, thus not presenting an indication for 
erythropoietin. Some data show that CRF can disappear 
spontaneously 6-8 weeks after the end of HT, but our patient 
was receiving HT, and was to be continued until progression 
or unacceptable toxicity, so that a medical withdrawal was 
not indicated. Although the timing and modality of treatment 
of PSA-only recurrence after radical prostatectomy and 
radiotherapy remains controversial, our patient had high-
risk disease deserving ﬁrst-line treatment.[18]
In CRF pathophysiology, a relevant impairment of 
neurotransmitter (serotoninergic, noradrenergic and 
dopaminergic) systems is present. The use of different 
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psychoactive drugs increasing neurotransmitter 
concentrations shows an effect in CRF treatment. The 
poor outcome of serotonergic drugs, as paroxetine and 
sertraline, on fatigue in randomized controlled trials 
could be due to their selective action on the serotonin 
reuptake.[13,16,19] Nevertheless, it is worth mentioning that 
a recent study stressed the role of tryptophan (a serotonin 
precursor) depletion in developing CRF and found a 
correlation between the higher degree of fatigue and 
lower tryptophan concentrations. Thus, a drug that acts 
on more than one mechanism could be appropriate.[13]
Modaﬁnil, a non-amphetamine psychostimulant, reduces 
CRF intensity.[12] Although the precise mechanism of 
modaﬁnil action has not been elucidated, it seems to 
rely on the interaction of adrenergic and dopaminergic 
transmission in prefrontal cortices.[20] Also, methylphenidate 
could facilitate excitatory synaptic signaling, mainly 
through strengthening catecholaminergic synaptic 
transmission. As a blocker of dopamine and norepinephrine 
transporters, it increases both extracellular dopamine and 
norepinephrine.[21,22]
Considering these data, the use of a drug like duloxetine, 
that has a pleiotropic action on these pathways, has some 
rationale in the treatment of CRF. Moreover, in our case, 
further beneﬁt was derived from its activity on urinary 
incontinence, thus promoting the patient’s sense of well-
being and, therefore, ameliorating his quality of life and 
increasing his compliance with physical therapy (mild 
exercise, daily walking), which has a therapeutic role in 
CRF and in social life.
In conclusion, a pilot placebo-controlled trial using 
duloxetine seems worthwhile since it acts on fatigue, 
urinary symptoms and depression, all often occurring 
in a complex and multidimensional disease as prostate 
cancer CRF.
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